MAP microba life sciences limited

3.26%

8.9¢

Ann: Q4 FY22 Quarterly Activities Report & Appendix 4C, page-4

First 4 Last

Share
Profile

Follow
turbo

727 Posts.

590

21/07/22

11:29

Post #: 62648906
Share

Originally posted by triage: ↑

Agree, impressive. I do have one concern and a couple of queries.

At first blush I worry that Luke Reid is being a tad cocky with this comment: "In FY23 we will advance into the clinic with our lead IBD asset MAP315 which we expect to generate significant value for shareholders".

I seem to recall seeing claims that only about 6% of products that make it through phase 1 clinical trial go onto being commercialised (and from memory about 40% of phase 2 and 80% of phase 3 end up making it to market). MAP315 is not even at the start line for a phase 1 trial. Unless LR knows something that he is not telling us I think "hope" rather than "expect" would have been closer to reality.

A couple of questions: I wonder how much of that revenue figure for Q4FY22 was from sale of testing services and how much was from sales to research clients. It seems to me that the the testing services are scalable but the research clients not so much.

Also given that the new distributorship arrangements were only bedded down at the end of the June quarter I wonder how much of a revenue boost is expected in coming quarters from the new distributors and the new product. I can find no guidance at all in either the quarterly or the presentation deck let alone the sort of estimates that Lefevre kindly shared a while back.

And finally, an observation: for every set of test data they get approval to keep and use not only do they get more revenue dollars they also get more grist for their AI. I follow a few companies that claim to be trying to use big data to disrupt normal order. Most likely some are pretenders and some will be failures. But Microba seems as well placed as any with its microbiome analysis skills and its growing dataset of both health and bugs.

Expand

What he means by "advance into the clinic" is begin human clinical trials, not commercialise which would still be several years away and uncertain as you point out.

And I agree, some breakdown of revenues and, in particular, guidance would have been helpful.

MAP Price at posting: 29.0¢ Sentiment: Hold Disclosure: Not Held
2 Upvote

0 Great analysis

Reply

Top Stories

BGL

Market shrugs off Bellevue's 'conservative' FY26 guidance

Why a Fed rate cut could obliterate your super – and no one's warning you

EMC

Everest Metals dips as company clocks low gold grades at Taipan, WA

PSC

Prospect Resources: Replicating the success of Arcadia with ~1b tonne copper ore target

Week 31 Wrap: Oz core CPI @ 2.7%! But here come tariffs. Again. Next Friday

I88

Infini Resources appoints Rohan Bone as CEO ahead of Phase 2 campaign

LKO

'Rising demand': Lakes Blue Energy starts well-timed Wombat-5 gas drilling

HZN

Crickets as Horizon Oil unveils new project picked up in Thailand

DES

DeSoto lands key exploration rights for Syncerus gold project in Guinea

AFP

AFT Pharmaceuticals outlines shareholder value focus in 2025 AGM

First 4 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 8.9¢		Change -0.003(3.26%)		Mkt cap ! $45.83M

Open	High	Low	Value	Volume
9.5¢	9.5¢	8.9¢	$67.73K	746.9K

Buyers (Bids)

No.	Vol.	Price($)
2	69744	8.9¢

Sellers (Offers)

Price($)	Vol.	No.
9.0¢	65000	2

View Market Depth

No.	Vol.	Price($)
2	69744	0.089
2	12552	0.088
1	30000	0.085
2	204868	0.084
1	10000	0.083

Price($)	Vol.	No.
0.090	65000	2
0.092	38901	1
0.099	195500	2
0.100	20000	1
0.105	109000	2

Last trade - 15.59pm 01/08/2025 (20 minute delay)

MAP (ASX) Chart

Ann: Q4 FY22 Quarterly Activities Report & Appendix 4C, page-4

Market shrugs off Bellevue's 'conservative' FY26 guidance

Why a Fed rate cut could obliterate your super – and no one's warning you

Everest Metals dips as company clocks low gold grades at Taipan, WA

Prospect Resources: Replicating the success of Arcadia with ~1b tonne copper ore target

Week 31 Wrap: Oz core CPI @ 2.7%! But here come tariffs. Again. Next Friday

Infini Resources appoints Rohan Bone as CEO ahead of Phase 2 campaign

'Rising demand': Lakes Blue Energy starts well-timed Wombat-5 gas drilling

Crickets as Horizon Oil unveils new project picked up in Thailand

DeSoto lands key exploration rights for Syncerus gold project in Guinea

AFT Pharmaceuticals outlines shareholder value focus in 2025 AGM

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Q4 FY22 Quarterly Activities Report & Appendix 4C, page-4

Top Stories

Market shrugs off Bellevue's 'conservative' FY26 guidance

Why a Fed rate cut could obliterate your super – and no one's warning you

Everest Metals dips as company clocks low gold grades at Taipan, WA

Prospect Resources: Replicating the success of Arcadia with ~1b tonne copper ore target

Week 31 Wrap: Oz core CPI @ 2.7%! But here come tariffs. Again. Next Friday

Infini Resources appoints Rohan Bone as CEO ahead of Phase 2 campaign

'Rising demand': Lakes Blue Energy starts well-timed Wombat-5 gas drilling

Crickets as Horizon Oil unveils new project picked up in Thailand

DeSoto lands key exploration rights for Syncerus gold project in Guinea

AFT Pharmaceuticals outlines shareholder value focus in 2025 AGM

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News